Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated December 21, 2022, under Item 8.01 to report a financing transaction with Pfizer Inc. The company is a clinical-stage pharmaceutical business developing ORIC-533, ORIC-114, and ORIC-944.
Transaction and Key Financial Metrics
| Item | Details |
|---|---|
| Investor | Pfizer Inc. |
| Securities issued | 5,376,344 shares of common stock |
| Purchase price | $4.65 per share |
| Gross proceeds | Approximately $25.0 million |
| Offering structure | Registered direct offering without an underwriter or placement agent |
| Expected closing | On or about December 23, 2022, subject to customary closing conditions |
The filing does not provide revenue, profit or loss, cash flow, operating margin, debt, cash balance, liquidity runway, or net proceeds after expenses.
Use of Proceeds and Material Changes
ORIC intends to use the net proceeds to fund ongoing and planned clinical trials, including studies of ORIC-533, ORIC-114, and ORIC-944, and for working capital and general corporate purposes.
The issuance will increase the company’s outstanding common shares and may dilute existing stockholders. The filing does not provide the pre-transaction share count or a quantified dilution percentage.
No comparable-period financial results or other period-over-period changes are reported in this 8-K.
Outlook, Risks, and Unusual Items
Completion of the transaction remained subject to customary closing conditions. Forward-looking statements concern the expected timing and completion of the financing and may differ based on market conditions, failure to satisfy closing conditions, or other risks.
The filing refers investors to the “Risk Factors” section of ORIC’s Quarterly Report on Form 10-Q filed November 7, 2022. The company stated that it assumes no obligation to update its forward-looking statements.
The securities purchase agreement, legal opinion, consent, and transaction press release were filed as exhibits. The filing states that contractual representations and warranties were made for the benefit of the parties and should not be treated as additional factual disclosures about the company.
Facts Investors Should Verify
- Whether the transaction closed on the anticipated date and on the stated terms.
- The final net proceeds after transaction expenses.
- The company’s post-issuance share count and resulting dilution to existing stockholders.
- Updated cash resources, quarterly cash burn, and expected liquidity runway.
- Development timelines, clinical progress, and funding requirements for ORIC-533, ORIC-114, and ORIC-944.
- Any additional terms or obligations in the full Securities Purchase Agreement.